Caprock Group LLC Purchases New Stake in Elevance Health, Inc. $ELV

Caprock Group LLC acquired a new position in Elevance Health, Inc. (NYSE:ELV) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,140 shares of the company’s stock, valued at approximately $1,638,000.

Other institutional investors also recently made changes to their positions in the company. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Elevance Health by 94.9% in the second quarter. Vermillion & White Wealth Management Group LLC now owns 76 shares of the company’s stock valued at $30,000 after purchasing an additional 37 shares during the period. BOK Financial Private Wealth Inc. acquired a new position in Elevance Health during the second quarter worth about $32,000. Physician Wealth Advisors Inc. increased its holdings in Elevance Health by 331.6% in the third quarter. Physician Wealth Advisors Inc. now owns 82 shares of the company’s stock valued at $26,000 after buying an additional 63 shares in the last quarter. Activest Wealth Management increased its holdings in Elevance Health by 66.7% in the third quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares in the last quarter. Finally, Glass Jacobson Investment Advisors llc boosted its stake in shares of Elevance Health by 400.0% during the 2nd quarter. Glass Jacobson Investment Advisors llc now owns 100 shares of the company’s stock worth $39,000 after acquiring an additional 80 shares in the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

More Elevance Health News

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Zacks raised its Q4 2027 EPS forecast to $4.75 (from $3.48), a sign that Zacks expects stronger late‑year profitability which could support the stock if sustained. Elevance Health (ELV) on MarketBeat
• Neutral Sentiment: MSN ran a stock‑perspective piece highlighting two reasons to like ELV and one caveat; the article reinforces bullish arguments around Elevance’s scale and business stability but also flags at least one risk investors should weigh. 2 reasons to like ELV (and 1 not so much)
• Negative Sentiment: Zacks issued multiple cuts to near‑term and full‑year estimates — lowering FY2026 (to $25.53 from $29.01), FY2027 (to $28.40 from $31.89) and trimming several Q1/Q2 2026–2027 quarterly forecasts — which signals weaker expected growth in the coming quarters and is a potential headwind for the stock. Zacks Research Lowers Earnings Estimates for Elevance Health

Elevance Health Stock Performance

NYSE:ELV opened at $346.49 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The firm has a market cap of $76.47 billion, a PE ratio of 13.79, a P/E/G ratio of 1.87 and a beta of 0.50. The firm has a 50 day simple moving average of $352.22 and a 200-day simple moving average of $331.73. Elevance Health, Inc. has a 1-year low of $273.71 and a 1-year high of $458.75.

Elevance Health (NYSE:ELV) last released its earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. The firm had revenue of $49.31 billion during the quarter, compared to analysts’ expectations of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same period in the previous year, the company earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, equities analysts expect that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be paid a $1.72 dividend. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a yield of 2.0%. Elevance Health’s payout ratio is currently 27.23%.

Analyst Ratings Changes

ELV has been the subject of several research reports. UBS Group set a $400.00 price objective on Elevance Health in a report on Thursday, January 29th. Morgan Stanley cut their price target on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 17th. Sanford C. Bernstein lowered their price objective on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating on the stock in a research note on Friday, January 30th. Mizuho set a $413.00 target price on shares of Elevance Health in a report on Friday, January 9th. Finally, Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 price target on the stock. in a report on Tuesday, February 3rd. Twelve research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.